Answers are grounded in this paper and cite their sources.
Purpose: To develop and validate a simple, rapid, sensitive and specific ultraperformance liquid chromatography mass spectrometry method for the quantification of the angiotensin II receptor antagonist, telmisartan (TEL), in human plasma.Methods: After simple protein precipitation using acetonitrile and methanol, TEL and internal standard (IS) abiraterone were separated on Acquity UPLC BEHTM C18 column (50 x 2.1 mm, i.d. 1.7 μm, Waters, USA) using a mobile phase consisting of acetonitrile: 8 mM ammonium acetate containing 0.15 % formic acid (v/v) (70:30) pumped at a flow rate of 0.3 mL/min and detected by tandem mass spectrometry with positive ion mode. The ion transitions recorded in multiple reaction monitoring mode were m/z 515.27→276.13 for telmisartan and m/z 350.1 > 156.0 for internal standard, abiraterone.Results: The assay exhibited a linear dynamic range of 1 – 200 ng/mL for telmisartan in human plasma with good correlation coefficient (0.995) and limit of quantitation of 1 ng/mL. The relative standard deviation for the intra- and inter-assay precision was between 0.75-11.50Conclusion: The developed UPLC-MS/MS method is simple, rapid and highly sensitive, and should thus be suitable for pharmacokinetic and toxicokinetic studies in both animals and humans.
No takes yet. Share an insight, caveat, or question.
Wani et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: